Department of Neurology, Show Chwan Memorial Hospital, Changhua, Taiwan.
Evid Based Complement Alternat Med. 2012;2012:414536. doi: 10.1155/2012/414536. Epub 2012 Jun 13.
Alzheimer's disease (AD) is an irreversible neurodegenerative disorder characterized by amyloid accumulation, neuronal death, and cognitive impairments. Yi-Chi-Tsung-Ming-Tang (YCTMT) is a traditional Chinese medicine and has never been used to enhance cognitive function and treat neurodegenerative disorders such as senile dementia. Whether YCTMT has a beneficial role in improving learning and memory in AD patients remains unclear. The present study showed that oral administration of YCTMT ameliorated amyloid-β- (Aβ(1-40)) injection-induced learning and memory impairments in rats, examined using passive avoidance and Morris water-maze tests. Immunostaining and Western Blot results showed that continuous Aβ(1-40) infusion caused amyloid accumulation and decreased acetylcholine level in hippocampus. Oral administration of medium and high dose of YCTMT 7 days after the Aβ(1-40) infusion decreased amyloid accumulation area and reversed acetylcholine decline in the Aβ(1-40)-injected hippocampus, suggesting that YCTMT might inhibit Aβ plague accumulation and rescue reduced acetylcholine expression. This study has provided evidence on the beneficial role of YCTMT in ameliorating amyloid-induced AD-like symptom, indicating that YCTMT may offer an alternative strategy for treating AD.
阿尔茨海默病(AD)是一种不可逆的神经退行性疾病,其特征是淀粉样蛋白积累、神经元死亡和认知障碍。益智通神明汤(YCTMT)是一种中药,从未被用于增强认知功能和治疗老年痴呆等神经退行性疾病。YCTMT 是否对改善 AD 患者的学习和记忆有有益作用尚不清楚。本研究表明,益智通神明汤口服给药可改善 Aβ(1-40)注射诱导的大鼠学习和记忆障碍,通过被动回避和 Morris 水迷宫试验进行检测。免疫染色和 Western Blot 结果表明,连续 Aβ(1-40)输注导致海马区淀粉样蛋白积累和乙酰胆碱水平下降。Aβ(1-40)输注后 7 天给予中、高剂量的益智通神明汤口服给药可减少淀粉样蛋白积累面积,并逆转 Aβ(1-40)注射海马区乙酰胆碱的下降,表明 YCTMT 可能抑制 Aβ 斑块积累并挽救减少的乙酰胆碱表达。本研究为益智通神明汤改善淀粉样蛋白诱导的 AD 样症状提供了证据,表明益智通神明汤可能为治疗 AD 提供一种替代策略。